Celcuity (CELC) Competitors $13.82 -0.04 (-0.28%) As of 03:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. ADUS, PACS, ARDT, LFST, PGNY, GRAL, NHC, TDOC, VRDN, and AHCOShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Addus HomeCare (ADUS), PACS Group (PACS), Ardent Health (ARDT), LifeStance Health Group (LFST), Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), and AdaptHealth (AHCO). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Addus HomeCare PACS Group Ardent Health LifeStance Health Group Progyny GRAIL National HealthCare Teladoc Health Viridian Therapeutics AdaptHealth Celcuity (NASDAQ:CELC) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Do analysts recommend CELC or ADUS? Celcuity currently has a consensus target price of $28.40, suggesting a potential upside of 105.48%. Addus HomeCare has a consensus target price of $142.57, suggesting a potential upside of 30.04%. Given Celcuity's higher probable upside, research analysts plainly believe Celcuity is more favorable than Addus HomeCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more volatility & risk, CELC or ADUS? Celcuity has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Addus HomeCare has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Is CELC or ADUS more profitable? Addus HomeCare has a net margin of 6.52% compared to Celcuity's net margin of 0.00%. Addus HomeCare's return on equity of 9.23% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets CelcuityN/A -96.21% -49.44% Addus HomeCare 6.52%9.23%6.96% Which has better valuation & earnings, CELC or ADUS? Addus HomeCare has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelcuityN/AN/A-$111.78M-$3.03-4.56Addus HomeCare$1.15B1.75$73.60M$4.4324.75 Does the media prefer CELC or ADUS? In the previous week, Addus HomeCare had 3 more articles in the media than Celcuity. MarketBeat recorded 7 mentions for Addus HomeCare and 4 mentions for Celcuity. Addus HomeCare's average media sentiment score of 1.14 beat Celcuity's score of 0.81 indicating that Addus HomeCare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Addus HomeCare 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals hold more shares of CELC or ADUS? 63.3% of Celcuity shares are owned by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are owned by institutional investors. 15.8% of Celcuity shares are owned by company insiders. Comparatively, 4.6% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAddus HomeCare beats Celcuity on 14 of the 16 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.31M$2.93B$5.50B$9.40BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-4.5720.2928.1319.86Price / SalesN/A259.75424.9198.68Price / CashN/A42.3835.5357.53Price / Book4.447.808.235.71Net Income-$111.78M-$55.11M$3.24B$257.80M7 Day Performance1.48%2.34%0.66%1.12%1 Month Performance17.33%13.02%8.07%11.30%1 Year Performance-23.94%1.46%28.44%16.88% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity2.1048 of 5 stars$13.82-0.3%$28.40+105.5%-25.8%$524.31MN/A-4.5740ADUSAddus HomeCare4.9753 of 5 stars$110.62-1.1%$142.57+28.9%-11.7%$2.06B$1.15B24.9749,703Positive NewsAnalyst ForecastPACSPACS Group2.7867 of 5 stars$12.51-4.8%$34.29+174.1%-62.3%$2.00B$3.11B0.0032,433News CoverageARDTArdent Health3.3757 of 5 stars$13.34-0.4%$20.67+54.9%N/A$1.92B$5.97B8.1824,900News CoverageAnalyst DowngradeLFSTLifeStance Health Group3.0626 of 5 stars$4.68-2.3%$8.50+81.6%-22.3%$1.86B$1.25B-46.8010,218PGNYProgyny1.0759 of 5 stars$21.450.0%$23.45+9.3%-23.3%$1.84B$1.17B37.63310Analyst ForecastGRALGRAIL0.6647 of 5 stars$44.85-4.0%$31.50-29.8%+88.2%$1.68B$125.60M-0.741,360Positive NewsNHCNational HealthCareN/A$104.23-3.9%N/A-22.4%$1.68B$1.37B13.0612,400TDOCTeladoc Health2.7314 of 5 stars$8.06-2.8%$9.60+19.1%-21.7%$1.45B$2.57B-1.365,500VRDNViridian Therapeutics2.9961 of 5 stars$15.89+1.4%$37.56+136.3%+5.1%$1.28B$300K-4.1350AHCOAdaptHealth3.8247 of 5 stars$9.25-0.8%$13.40+44.9%-19.3%$1.26B$3.26B16.2310,500Gap Down Related Companies and Tools Related Companies Addus HomeCare Competitors PACS Group Competitors Ardent Health Competitors LifeStance Health Group Competitors Progyny Competitors GRAIL Competitors National HealthCare Competitors Teladoc Health Competitors Viridian Therapeutics Competitors AdaptHealth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CELC Stock Alerts